Market Overview

Nanosphere Wins FDA Clearance to Market CYP2C19 Mutations Detection Test

Related NSPH
Morning Market Movers
Morning Market Movers

Nanosphere, Inc. (Nasdaq: NSPH) announced today the US FDA granted 510(k) clearance permitting marketing of its CYP2C19 Nucleic Acid Test (CYP2C19 Test) on the automated sample-to-result Verigene^® System.

Posted-In: News FDA

 

Most Popular

Related Articles (NSPH)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters